This is our Xequel. Get ready to watch an exciting story unfold. Read all about it below, and reach out to learn more.
– Presentation Will Highlight Positive Clinical Trial Data on iNexin™ for Treatment of Corneal Injury – – Xequel Launches New
Seasoned Biopharma Executives Bring Significant Clinical Development and Commercial Expertise Charleston, SC and Fort Worth, TX, July 26, 2022 –
Excellent Safety and Tolerability Profile for iNexin™ for the Treatment of Corneal Injury Early Efficacy Signals Provide Rationale to Advance
Jerry St. Peter Named Chief Executive Officer and Member of the Board of Directors Wes Brazell Named Chief Financial Officer
1501 Belle Isle Avenue
Suite 220
Mount Pleasant, South Carolina 29464
843.388.3276